Business Wire

Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell ...

Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ ...
Yahoo Finance

Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 01, 2025--(BUSINESS WIRE)--Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a ...